Stock Notification: Sandomigran, pizotifen 0.5 mg (as maleate) tablet

Sandomigran, pizotifen 0.5 mg (as maleate) tablet AUST R 69608

In July 2015, AFT Pharmaceuticals Pty Ltd took over the sponsorship of Sandomigran tablets from Novartis Pharmaceuticals Pty Ltd.

AFT Pharmaceuticals Pty Ltd are currently out of stock of this product at their warehouse. This situation has arisen as a consequence of the change of sponsorship affecting production of the finished product.

It is our understanding that wholesalers are typically holding between 4 and 6 weeks stock of the product which we are hoping this stock holding will prevent unavailability of the product to patients.

We are arranging to take delivery of 15,000 units of stock which will expire in June 2016. This stock is expected to be available for distribution by late November 2015. In addition, AFT Pharmaceuticals have an application with the TGA which when approved will allow for a further 78,000 units to become available.

It is anticipated that normal production and subsequent supply of the product will re-commence from February 2016.

We thank you for your understanding of the situation.

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More

March 5, 2024

AFT makes further progress in international markets

AFT Pharmaceuticals provides an update on recent progress it has made in international markets….

Read More